FSTX News and Press, F-star Therapeutics Inc Com From 09/15/22

F-star Therapeutics Inc. ( NASDAQ: FSTX ) dropped 2% after the company disclosed that a national security review of its sale to Sino-Biopharma ( OTCPK:SBHMY ) has moved into an extended review. The CFIUS review of the deal is expected to continue for another 45 day...

The following slide deck was published by F-star Therapeutics, Inc. in conjunction with their 2022 Q2 earnings call. For further details see: F-star Therapeutics, Inc. 2022 Q2 - Results - Earnings Call Presentation

F-star Therapeutics press release ( NASDAQ: FSTX ): Q2 GAAP EPS of -$0.88. Cash and cash equivalents were $53.0 million as of June 30, 2022, compared to $78.5 million at December 31, 2021. For further details see: F-star Therapeutics GAAP EPS of -$0.88

Previously announced agreement for F-star Therapeutics to be acquired by invoX Pharma; transaction expected to close in the second half of 2022 License Agreement with Takeda to Develop and Commercialize a Novel Next-Generation Immuno-Oncology Bispecific Antibody Therapeutic ...

F-star Therapeutics announced in June that they would be acquired by InvoX, causing shares to soar. InvoX is pricing their bid at $7.12 a share; the offer is set to close on the third of August. As of the time of writing, the stock currently trades at $6.20, representing a discoun...

NEW YORK, NY / ACCESSWIRE / July 22, 2022 / Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Steel Connect, Inc. (NASDAQ:STCN)'s ...

F-star Therapeutics ( NASDAQ: FSTX ) on Wednesday said it had entered into a licensing agreement with Japanese pharmaceutical major Takeda ( NYSE: TAK ) to develop a cancer immune therapy. As per the terms of the deal, FSTX will grant Takeda a worldwide license...

CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., July 20, 2022 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX) (“F-star”), operating through its subsidiary, F-star Therapeutics Ltd., a clinical-stage biopharmaceutical company pioneering bispecifics in immunot...

The biotech investment sector has always been its own market, very distinct from other sectors. So it was no surprise that when most sectors turned slowly upward after the pandemic-inspired crash, Biotech (XBI) rose 164%, exceeding the overall market (SPY) performance by triple digits. Then, a...

NEW YORK, NY / ACCESSWIRE / June 30, 2022 / Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Hemisphere Media Group, Inc. (NASDAQ...